Morphine Sulfate
NDC Package 0228-4347-11
Package Information
Morphine Sulfate is extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.Limitations of UseBecause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions (5.1)], reserve morphine sulfate extended-release for use in patients for whom alternative treatment options (e.g., non- opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.Morphine sulfate extended-release is not indicated as an as-needed (prn) analgesic. Marketed by Actavis Pharma, Inc., this product is identified by NDC 0228-4347 and is authorized under FDA application ANDA203849.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0228 - Actavis Pharma, Inc.
- 0228-4347 - Morphine Sulfate
- 0228-4347-11 - 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
- 0228-4347 - Morphine Sulfate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0228-4347-11 identifies a specific commercial package of 100 tablet, film coated, extended release in 1 bottle of Morphine Sulfate, labeled by Actavis Pharma, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Actavis Pharma, Inc. on October 26, 2015. The current certification is valid through March 31, 2022.
How is this Actavis Pharma, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00228434711. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.